A specific postmarketing study of clavulanic acid/amoxicillin (1: 14) dry syrup for pediatric in pediatric patients with infection

Kazunobu Ouchi, Satoshi Iwata, Hideyuki Okano, Hiroharu Abe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A specific postmarketing study of a combination preparation of penicillin antibiotic and β-lactamase inhibitor, clavamox® dry syrup for pediatric (clavulanic acid/amoxicillin (1:14), CVA/AMPC (1:14)), was conducted from November 2007 to October 2008 to evaluate postmarketing safety and efficacy in pediatric patients with infections of the respiratory tract, skin, and urinary tract. Subjects were 363 cases from 68 medical institutes. Safety was evaluated for 337 cases and efficacy for 308. Adverse drug reactions (ADRs) occurred in 337 cases, or 12.8% (43/337 cases). The most frequently observed ADR was diarrhea, observed in 11.9% (40/337 cases). The diarrhea incidence tended to be higher in younger children, but symptoms were mild and were resolved or reduced during administration or after withdrawal of the drug. Efficacy in 308 cases was 95.1% (293/308 cases). Efficacy by infection type was 95.4% for the respiratory tract (267/280 cases), 96.6% for the skin (28/29 cases), and 1/2 cases for the urinary tract. Efficacy for major causative organism of infections studied, including Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, and Moraxella catarrhalis, was 91.7-100%.

Original languageEnglish
Pages (from-to)438-452
Number of pages15
JournalJapanese Journal of Chemotherapy
Volume57
Issue number5
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Amoxicillin-Potassium Clavulanate Combination
Drug-Related Side Effects and Adverse Reactions
Urinary Tract
Diarrhea
Pediatrics
Safety
Moraxella (Branhamella) catarrhalis
Skin
Streptococcus pyogenes
Haemophilus influenzae
Streptococcus pneumoniae
Infection
Respiratory Tract Infections
Penicillins
Respiratory System
Staphylococcus aureus
Incidence
Pharmaceutical Preparations

Keywords

  • Child
  • Clavulanic acid/amoxicillin
  • Efficacy
  • Postmarketing surveillance
  • Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A specific postmarketing study of clavulanic acid/amoxicillin (1 : 14) dry syrup for pediatric in pediatric patients with infection. / Ouchi, Kazunobu; Iwata, Satoshi; Okano, Hideyuki; Abe, Hiroharu.

In: Japanese Journal of Chemotherapy, Vol. 57, No. 5, 2009, p. 438-452.

Research output: Contribution to journalArticle

Ouchi, Kazunobu ; Iwata, Satoshi ; Okano, Hideyuki ; Abe, Hiroharu. / A specific postmarketing study of clavulanic acid/amoxicillin (1 : 14) dry syrup for pediatric in pediatric patients with infection. In: Japanese Journal of Chemotherapy. 2009 ; Vol. 57, No. 5. pp. 438-452.
@article{3367af41327d40e5ae837dae0c4d0d94,
title = "A specific postmarketing study of clavulanic acid/amoxicillin (1: 14) dry syrup for pediatric in pediatric patients with infection",
abstract = "A specific postmarketing study of a combination preparation of penicillin antibiotic and β-lactamase inhibitor, clavamox{\circledR} dry syrup for pediatric (clavulanic acid/amoxicillin (1:14), CVA/AMPC (1:14)), was conducted from November 2007 to October 2008 to evaluate postmarketing safety and efficacy in pediatric patients with infections of the respiratory tract, skin, and urinary tract. Subjects were 363 cases from 68 medical institutes. Safety was evaluated for 337 cases and efficacy for 308. Adverse drug reactions (ADRs) occurred in 337 cases, or 12.8{\%} (43/337 cases). The most frequently observed ADR was diarrhea, observed in 11.9{\%} (40/337 cases). The diarrhea incidence tended to be higher in younger children, but symptoms were mild and were resolved or reduced during administration or after withdrawal of the drug. Efficacy in 308 cases was 95.1{\%} (293/308 cases). Efficacy by infection type was 95.4{\%} for the respiratory tract (267/280 cases), 96.6{\%} for the skin (28/29 cases), and 1/2 cases for the urinary tract. Efficacy for major causative organism of infections studied, including Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, and Moraxella catarrhalis, was 91.7-100{\%}.",
keywords = "Child, Clavulanic acid/amoxicillin, Efficacy, Postmarketing surveillance, Safety",
author = "Kazunobu Ouchi and Satoshi Iwata and Hideyuki Okano and Hiroharu Abe",
year = "2009",
language = "English",
volume = "57",
pages = "438--452",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "5",

}

TY - JOUR

T1 - A specific postmarketing study of clavulanic acid/amoxicillin (1

T2 - 14) dry syrup for pediatric in pediatric patients with infection

AU - Ouchi, Kazunobu

AU - Iwata, Satoshi

AU - Okano, Hideyuki

AU - Abe, Hiroharu

PY - 2009

Y1 - 2009

N2 - A specific postmarketing study of a combination preparation of penicillin antibiotic and β-lactamase inhibitor, clavamox® dry syrup for pediatric (clavulanic acid/amoxicillin (1:14), CVA/AMPC (1:14)), was conducted from November 2007 to October 2008 to evaluate postmarketing safety and efficacy in pediatric patients with infections of the respiratory tract, skin, and urinary tract. Subjects were 363 cases from 68 medical institutes. Safety was evaluated for 337 cases and efficacy for 308. Adverse drug reactions (ADRs) occurred in 337 cases, or 12.8% (43/337 cases). The most frequently observed ADR was diarrhea, observed in 11.9% (40/337 cases). The diarrhea incidence tended to be higher in younger children, but symptoms were mild and were resolved or reduced during administration or after withdrawal of the drug. Efficacy in 308 cases was 95.1% (293/308 cases). Efficacy by infection type was 95.4% for the respiratory tract (267/280 cases), 96.6% for the skin (28/29 cases), and 1/2 cases for the urinary tract. Efficacy for major causative organism of infections studied, including Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, and Moraxella catarrhalis, was 91.7-100%.

AB - A specific postmarketing study of a combination preparation of penicillin antibiotic and β-lactamase inhibitor, clavamox® dry syrup for pediatric (clavulanic acid/amoxicillin (1:14), CVA/AMPC (1:14)), was conducted from November 2007 to October 2008 to evaluate postmarketing safety and efficacy in pediatric patients with infections of the respiratory tract, skin, and urinary tract. Subjects were 363 cases from 68 medical institutes. Safety was evaluated for 337 cases and efficacy for 308. Adverse drug reactions (ADRs) occurred in 337 cases, or 12.8% (43/337 cases). The most frequently observed ADR was diarrhea, observed in 11.9% (40/337 cases). The diarrhea incidence tended to be higher in younger children, but symptoms were mild and were resolved or reduced during administration or after withdrawal of the drug. Efficacy in 308 cases was 95.1% (293/308 cases). Efficacy by infection type was 95.4% for the respiratory tract (267/280 cases), 96.6% for the skin (28/29 cases), and 1/2 cases for the urinary tract. Efficacy for major causative organism of infections studied, including Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, and Moraxella catarrhalis, was 91.7-100%.

KW - Child

KW - Clavulanic acid/amoxicillin

KW - Efficacy

KW - Postmarketing surveillance

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=71049191478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049191478&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:71049191478

VL - 57

SP - 438

EP - 452

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 5

ER -